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ABSTRACT
Objective: To determine the outcome and cost-
effectiveness of nurse-led care in the community for
people with rheumatoid arthritis (RA).
Design: Non-randomised pragmatic study.
Setting: Primary (7 primary care practices) and
secondary care (single centre) in the UK.
Methods: In a single area, pragmatic non-randomised
study, we assessed the outcome, cost-effectiveness of
community-based nurse-led care (NLC) compared with
rheumatologist-led outpatient care (RLC). Participants
were 349 adults (70% female) with stable RA assessed
at baseline, 6 and 12 months. In the community NLC
arm there were 192 participants. Outcome was
assessed using Stanford Health Assessment
Questionnaire (HAQ). The economic evaluation
(healthcare perspective) estimated cost relative to
change in HAQ and quality-adjusted life years (QALY)
derived from EQ-5D-3L. We report complete case and
multiple imputation results from regression analyses.
Results: The demographics and baseline
characteristics of patients in the community group
were comparable to those under hospital care apart
from use of biological disease-modifying antirheumatic
drugs (DMARDS), which were adjusted for in the
analysis. The mean incremental cost was estimated to
be £224 less for RLC compared to the community
NLC, with wide CIs (CI –£213 to £701, p=0.296).
Levels of functional disability were not clinically
significantly higher in the community NLC group: HAQ
0.096 (95% CI −0.026 to 0.206; p=0.169) and QALY
0.023 (95% CI −0.059 to 0.012; p=0.194).
Conclusions: The results suggest that community
care may be associated with non-significant higher
costs with no significant differences in clinical
outcomes, and this suggests a low probability that it is
cost-effective.
INTRODUCTION
Rheumatoid arthritis (RA) is a common
chronic destructive arthropathy. The overall
prevalence of RA in the UK is 0.81%,1 with
the majority of patients requiring long-term
treatment with immunosuppressant drugs. In
2009, it was estimated by the national audit
ofﬁce that RA cost the National Health
Service (NHS) £560 million per year.2
The traditional model of RA treatment is
for all follow-up to be conducted by rheuma-
tologists in hospital departments; however,
NHS policy currently favours moving chronic
disease management from hospital-based
clinics into the community.3 Over the past
three decades, rheumatology nurse practi-
tioners (RP) (also known as clinical nurse
specialists) have become an accepted part of
the multidisciplinary team and complete
many tasks traditionally performed by rheu-
matologists, including joint injections and
prescribing.4 5 RPs assess disease activity,
monitor effects of therapy, provide patient
education, psychological support, care coord-
ination and some RPs can prescribe medica-
tion and recommend medication changes.6 7
Patients attending clinics with nurse led care
(NLC) have good outcomes in terms of phys-
ical function, disease activity, quality of life,
pain, fatigue, stiffness, psychological function
and satisfaction.8–11 Convenience, continuity
of care, and proximity of services to home
are considered advantages of community
NLC.12 However, patients with RA need
Strengths and limitations of this study
▪ Observational study of the cost-effectiveness and
outcomes of community nurse-led care for
rheumatoid arthritis, thereby reflecting real life
care.
▪ Include 349 patients followed for 12 months.
▪ Compliments studies of nurse-based hospital
care.
▪ Single area which may limit generalisability.
▪ Final recruitment less than planned.
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ready access to other members of the multidisciplinary
team such as physiotherapists and occupational thera-
pists. Thus, it is not clear whether the move to commu-
nity care will disrupt the use and development of
multidisciplinary teams.
Various models of multidisciplinary care were investi-
gated in a multicentre study in Holland and NLC was
shown to be more cost-effective than inpatient care or
day patient care.13 The cost-effectiveness and outcome
of nurse-led care in the UK has been evaluated in a
multicentre randomised controlled trial in a secondary
care setting and shown to be not inferior to
rheumatologist-led care (RLC).14 A recent study from
Denmark suggested that shared care and nurse-led care
cost less and provided broadly similar health outcomes
compared with rheumatologist outpatient care.15 For
consultants working in community-based clinics, it
seems that increased health beneﬁts are achieved at
increased cost;16–18 the same may not be true of nurses
whose employment costs are substantially lower than
doctors. What is not known is the cost-effectiveness of
community NLC, compared to traditional RLC.
In Norfolk, services have evolved with the develop-
ment of community NLC based in primary care, which
are entirely nurse led, without direct support from a
consultant. Thus, the opportunity arose to address the
research question as to the cost-effectiveness of commu-
nity NLC compared with RLC by means of a pragmatic
observational study.
METHODS
The aim of this study was to evaluate the health out-
comes and costs of RA services provided in primary and
secondary care. We designed an observational non-
randomised study to evaluate the clinical and cost-
effectiveness of independent community NLC, in com-
parison with standard RLC. We did not wish to disrupt
or alter the pattern of care and therefore, choose an
observational non-randomised study design.
Study population
Patients with established RA undergoing routine follow-up.
Patients fulﬁlled the American College of Rheumatology
(ACR) criteria for RA19 and were aged over 18 years. We
excluded patients with new onset RA (less than 1-year dur-
ation) or with severe functional impairment or very active
unstable disease as such patients would tend to be solely
cared for in secondary care. Patients were recruited at the
time of their routine secondary care outpatient or commu-
nity clinic appointment. We recruited from all the clinics
in primary care and from the main secondary care centre
to minimise selection bias.
Structure of rheumatology services in Norfolk
Norfolk is a rural county in the East of England with a
central secondary care hospital and satellite community
hospitals in addition to primary care centres. Patients
often have to travel signiﬁcant distances to access sec-
ondary care and hence, community-based care is more
convenient for them.
Community clinics
Nurse-led care in the community was provided by ﬁve
RPs in seven general practices (6 rural and 1 urban
within Norwich), with clinics held every 1–4 weeks. These
were nurse-led and independent of direct rheumatologist
input. Patients seen in these clinics were only referred for
a consultant opinion when needed. The RPs assessed
patients’ disease activity and their drug therapy for efﬁ-
cacy and side effects; however, prescriptions were pro-
vided by their general practitioners, and patients
requiring joint injections could access these via the main
secondary care hospital or the two community hospitals.
Hospital clinics
The secondary care service was provided by ﬁve consult-
ant rheumatologists, supported by specialist registrars
and RPs, based in one large teaching hospital and two
community hospitals. The RPs worked alongside the
medical staff but did not provide independent NLC. For
most of the study there were ﬁve RPs, some of whom
also worked in the primary care clinics. There was also
access to a day unit for intravenous therapies and
intra-articular injections, together with a full multidiscip-
linary team.
Sample size calculation
Based on a small difference between the groups
(a Cohen’s Effect Size of 0.35), 175 participants in each
group were required to confer 90% power without
adjustment for potential confounders. With an adjust-
ment (using a general linear model) for a potential con-
founding imbalance in HAQ at baseline and assuming
that the coefﬁcient of determination between groups
was no more than 0.25, then 235 participants per group
were required to confer 90% power.
Estimatation of costs
Measuring resource use
We used a modiﬁed version of a previously developed
resource-use questionnaire20 administered at baseline,
6 months and 12 months, participants were asked to
report the following items of resource use over the previ-
ous 6-month period:
▸ contacts with health professionals
▸ arthritis-related admissions to hospital or day-units
▸ arthritis-related tests and procedures, including
steroid injections
▸ arthritis-related prescribed medications—speciﬁcally
biological disease-modifying antirheumatic drugs
(DMARDs), non-biological DMARDs and opioid
analgesics
▸ time taken off work due to their arthritis
▸ travel costs associated to contact with healthcare
professionals
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Assigning costs to items of resource use
Costs were estimated using 2011/2012 ﬁnancial year
levels; NHS and personal social services (PSS) costs were
taken from a combination of Curtis21 and the National
Schedule of Reference Costs,22 (see online supplemen-
tary table S1). Participant travel costs were estimated
using a cost of £0.40 per mile for private car; speciﬁc
fees were requested for those who used public transport
or a taxi. Where full details of the usual method of
travel were not provided, mean imputation was used, to
estimate an overall travel cost for each participant.
The average rate of hourly earnings (in 2011)23 was
used to estimate the cost associated with lost productiv-
ity.24 However, since productivity costs may vary if differ-
ent costing methodologies were applied,25 these costs
are reported separately to the other aforementioned
costs, in subsequent sensitivity analysis.
Participants were asked to report the name, dose and
frequency of prescribed medications, and the number of
prescriptions in the past 6 months. We assigned costs to
those considered taken for RA purposes. Non-steroidal
anti-inﬂammatory drugs (NSAIDs) were excluded as we
could not discriminate between those used for RA or
other purposes. Unit costs were taken from the prescrip-
tion cost analysis.26
Overall costs
Total healthcare costs, for both the community and
hospital groups, were estimated by summing the costs
associated with the aforementioned items of resource
use. Overall costs were estimated by summing total
healthcare, travel and lost productivity costs.
Measuring outcomes
We used the Stanford Health Assessment Questionnaire
(HAQ) to assess disability. We report cost-effectiveness in
terms of the incremental cost of community delivery per
incremental change on the HAQ scale. Participants
completed the HAQ at 0, 6 months and 12 months.
To estimate levels of health-related quality of life, parti-
cipants completed the EQ-5D-3L27 at baseline, 6 months
and 12 months. The York A1 tariff was applied to these
responses in order to enable an associated utility score
(this has a scale where 0=death and 1=full health) to be
calculated.28 The area under the curve method29 was
used to estimate the total quality adjusted life year
(QALY) score over the 12-month follow-up period,
where it was assumed EQ-5D scores changed linearly
between time points. Completion of the EQ-5D enabled
a cost-utility analysis to be undertaken using cost per
QALY gained.
Economic analysis
Costs were calculated from the healthcare perspective
(NHS and Personal Social Services)30 and included only
those participants who returned both the 6-month, and
12-month follow-up questionnaire. We compared the
cost-effectiveness of nurse-led clinics in the community
(‘community’) to hospital-based outpatient care (‘hos-
pital’). As all trial follow-up was completed within
12 months, no discounting was applied to either costs or
outcomes.
In the primary analysis, a complete case approach was
adopted, where complete cost and outcome data (either
HAQ/QALYs based on the EQ-5D) was required.
However, in order to include all available data, multiple
imputation was undertaken as part of a sensitivity ana-
lysis. We imputed missing (disaggregated) costs, EQ-5D
and HAQ data at each time point, following mi proce-
dures in StataSE 12. Imputation took place in ﬁve cycles,
the estimates from which were then pooled and calcu-
lated using Rubin’s rules.31 32
Bivariate linear regression was used to estimate the
mean cost difference (incremental cost) between the
two groups (this was estimated for total healthcare and
overall costs), and the mean incremental effect (differ-
ence in QALYs/HAQ), where the baseline costs,
outcome measures (EQ-5D-3L/HAQ), age and gender
acted as covariates.33 In order to estimate the level of
uncertainty associated with the decision regarding cost-
effectiveness, we also estimated 95% CIs and the cost-
effectiveness acceptability curve (CEAC). Using a boot-
strapped sample, the probability that the community
arm had a higher net beneﬁt compared to hospital care
(vertical axis) was plotted for each value of λ (horizontal
axis). We also graphically represent the bootstrapped
cost-effect pairs on a cost-effectiveness plane.34–37
RESULTS
Participants
We approached 204 patients in the community and 168
in the hospital arm. Primary analysis was on complete
cost and QALY data at all three time points, which con-
sisted of 205 participants (111 in community arm; 94 in
hospital arm). Participant ﬂow through the study is
shown in ﬁgure 1, and basic demographic data in table 1.
Costs
For those who completed the cost questionnaires, mean
level of health resource use and costs for each of the
two groups are summarised in table 2, with further
details on health professional visits summarised in
online supplementary table S2. Mean health profes-
sional contact costs were marginally higher for the hos-
pital group (£642 compared with £581). There was little
difference between the two groups with regard to the
mean cost associated with hospital/day-case admissions,
steroid use or tests and procedures.
Travel costs were marginally lower in the community
arm compared with hospital (£62 vs £69). In the com-
munity group, 93.5% reported taking no time off work
(due to their arthritis) compared with 85.8% of those in
the hospital group in the 12-month follow-up period,
the mean values equated to 3.26 days and 3.71 days,
respectively.
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Overall, health resource use associated with commu-
nity NLC was very similar to that in hospital-based care
apart from one aspect: prescribed medications. At base-
line, RA participants in community arm were using £553
medications over 6 months, compared to £223 in
hospital. Over the 1-year follow-up, this disparity had
increased to £1567 per participant in the community
arm compared with £676 for hospital-treated patients.
The largest cost difference appeared with biological
DMARDS, but for opioid analgesics, costs were also
slightly higher in the community arm compared with
hospital- based participants.
Outcomes
EQ-5D-3L
EQ-5D scores at baseline, 6 and 12 month are sum-
marised in table 3. Hospital participants EQ-5D out-
comes improve slightly (+0.043) over the 12-month
follow-up, whereas community participants EQ-5D out-
comes decline slightly (−0.015) over same period. This
represents an incremental QALY gain of 0.026 QALYs in
the hospital arm compared to community, which is neg-
ligible in terms of quality of life impact.
Health Assessment Questionnaire
HAQ outcomes were compared for participants who
completed both baseline and 12-month assessments
(119 in community arm, 106 in hospital; table 3). At
baseline, the mean HAQ score was slightly higher in the
community arm (0.956 compared with 0.913 in hos-
pital). At 12 months, disability had progressed further in
the community arm (1.061 compared with 0.921 in hos-
pital). Based on the regression analysis, it was estimated
Figure 1 Patient flow through
the study.
Table 1 Baseline characteristics of study population
stratified by study group
Baseline
characteristics
Community
(n=192)
Hospital
(n=154)
Women, n (%) 136 (70.10) 106 (69.28)
Age, years; mean (SD) 65.56 (10.56) 64.86 (11.39)
Disease duration, years;
mean (SD) (n=172; 147)
13.82 (11.33) 12.91 (11.45)
Baseline RA regimen
Methotrexate (%) 155 (80.7) 128 (83.1)
Sulfasalazine (%) 38 (19.8) 25 (16.2)
Hydroxychloroquine (%) 40 (20.8) 40 (26.0)
Leflunomide (%) 17 (8.8) 12 (7.8)
Prednisolone (%) 25 (13.0) 22 14.3)
Biological DMARDs (%) 17 (8.8) 3 (1.9)
Opioid analgesics (%) 43 (22.4) 31 (20.1)
Baseline outcome scores, mean (SD)
HAQ (182; 149)* 1.01 (0.75) 0.98 (0.78)
EQ-5D-3L (183; 146)* 0.635 (0.258) 0.624 (0.307)
*Figures in brackets refer to the number of completed forms for
each group.
DMARDs, disease-modifying antirheumatic drugs; HAQ, Health
Assessment Questionnaire; RA, rheumatoid arthritis.
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that there was a 0.096 difference in progression (scores
had worsened more in the community arm compared to
the hospital). This is well below the minimal clinical
important difference of 0.22.38
Cost-effectiveness analysis
Based on those with complete cost and EQ-5D data, the
mean incremental total NHS cost was estimated to be
£224 less for the hospital group compared to the commu-
nity group (CI –£213 to £701, p=0.296; table 4). When
travel costs and lost productivity (time off work) costs
were included, the incremental cost was £917 (CI £145 to
£1688, p=0.020). The incremental QALY gain (for the
community arm compared to the hospital) was negli-
gible, estimated to be −0.023 (–0.059 to 0.012, p=0.194).
This demonstrates no signiﬁcant difference between
each of the groups with regard to either healthcare costs,
travel, lost productivity or overall costs or QALYs. When
comparing the healthcare costs to clinical outcomes, as
measured by the HAQ, we found the community group
had higher mean costs (mean difference=£127, CI −£369
to £624, p=0.589) and a higher level of functional disabil-
ity (mean difference=0.096 CI −0.026 to 0.206, p=0.169).
In all analyses, outcomes (QALYs or HAQ) were worse in
the community arm; however, the difference was
negligible. The community group had higher mean
overall costs and lower mean effect. These ﬁndings were
consistent when using the imputed (full) data set.
Sensitivity analysis
To account for the marked impact of biological DMARD
costs to overall cost-effectiveness, we also report health-
care costs excluding medication costs, NHS costs adjust-
ing for baseline biologics, and NHS and social costs
adjusting for baseline biological use (table 4). Excluding
those who received biologics at baseline, the community
arm continued to cost more than hospital care, but at a
lesser margin of £234 (CI −£201 to £669) less using
cost/QALY, and £241 (CI −£501 to £983) less than hos-
pital care using cost/HAQ.
CE plane
The cost-effectiveness plane for 2000 bootstrap replica-
tions comparing cost and QALYs of community RA care
compared to hospital setting is shown in ﬁgure 2 and B.
Most cost-effect pairs are located in the north-west quad-
rant, suggesting community care is associated with
higher costs and unfavourable outcomes. Data from the
multiple imputed data set is provided in online
supplementary ﬁgure S1A.
Table 2 Mean (range) levels of resource use and associated costs
Levels of resource use Mean cost (£)
Item
Community
n=130
Hospital
n=100 Community Hospital
Health professional contacts 14.6 (1 to 69) 16.7 (1 to 63) £581 (£41 to £5574) £642 (£40 to £3917)
Hospital/day-case admissions* 0.14 (0 to 5) 0.18 (0 to 11) £213 (£0 to £6435) £209 (£0 to £5958)
Tests and procedures* 2.7 (0 to 10) 2.6 (0 to 9) £33 (£0 to £230) £34 (£0 to £196)
Steroid injections 0.57 (0 to 7) 0.45 (0 to 4) £73 (£0 to £875) £44 (£0 to £500)
NHS costs excluding medications – – £900 (£53 to £7655) £928 (£44 to £7678)
Biological DMARDs 0.13 0.04 £1210 (£0 to £9295) £323 (£0 to £9295)
Non-biological DMARDs 1.41 1.43 £330 (£0 to £3063) £332 (£0 to £1554)
Opioid analgesics 0.16 0.18 £27 (£0 to £745) £21 (£0 to £577)
Overall NHS costs £2467 (£58 to £16 811) £1604 (£153 to £13 835)
Travel £62 (£0 to £840) £69 (£0 to £488)
Time off work (days)* 3.26 (0 to 160) 3.71 (0 to 182) £306 (£0 to £15 698) £329 (£0 to £17 856)
Overall NHS and lost
productivity costs
– – £2835 (£61 to £16 953) £1975 (£153 to £18 806)
*Based on complete case data set.
DMARDs, disease-modifying antirheumatic drugs; NHS, National Health Service.
Table 3 Estimates of the mean EQ-5D and HAQ over the 12-month follow-up period
EQ-5D and QALY score HAQ score
Community Hospital Community Hospital
n=122 N=105 N=119 N=106
Baseline 0.654 (–0.181 to 1) 0.646 (–0.184 to 1) 0.956 (0 to 3) 0.913 (0 to 3)
6 month 0.633 (–0.073 to 1) 0.646 (–0.181 to 1) 1.058 (0 to 2.88) 0.925 (0 to 3)
12 month 0.639 (–0.181 to 1) 0.689 (–0.015 to 1) 1.061 (0 to 2.88) 0.921 (0 to 3)
QALY score 0.639 (–0.071 to 1) 0.665 (–0.086 to 1)
HAQ, Health Assessment Questionnaire; QALY, quality-adjusted life years.
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The cost-effectiveness acceptability curve (CEAC) is
shown in ﬁgures 2C and D. With a probability of being
more cost-effective than hospital care in less than 10% at
all thresholds, community care is clearly less favourable.
Data from the multiple imputed data set is provided in
the online supplementary ﬁgure 1B.
DISCUSSION
This study is the ﬁrst to provide data on the cost-
effectiveness of routine community NLC of patients with
RA. We compared patients with stable RA managed in a
community NLC setting with those managed in trad-
itional RLC. The two groups were reasonably well
Table 4 Cost-effectiveness results
Complete case data set
Costs (community compared to
Hospital)
Outcomes (community
compared to Hospital)
Cost utility(cost/QALY) N Costs CI p Value QALY* CI p Value
NHS costs 199 £244.24 −213 701 0.296 −0.023 −0.059 0.012 0.194
NHS and social costs 199 £917.21 145 1688 0.022 −0.023 −0.056 0.016 0.194
Excludes patients on biological DMARDs 185 £234.40 −201 669 0.376 −0.026 −0.055 0.018 0.259
Healthcare excluding medication costs 199 £51.07 −324 426 0.790 −0.024 −0.058 0.010 0.167
NHS costs, adjusting for baseline biologics 199 £241.13 −217 699 0.302 −0.023 −0.056 0.016 0.194
NHS+social costs, adjusting for baseline
biologics
199 £488.71 −219 1197 0.176 −0.023 −0.056 0.016 0.194
Cost-effectiveness (cost/HAQ) Costs CI HAQ† CI
NHS costs 194 £127.09 −369 624 0.589 0.096 −0.026 0.206 0.169
NHS and social costs 194 £759.86 −38 1558 0.062 0.073 −0.050 0.195 0.248
Excludes patients on biological DMARDs 177 £240.76 −501 983 0.525 0.076 −0.054 0.206 0.251
Healthcare excluding medication costs 194 £73.72 −573 719 0.737 0.086 −0.035 0.207 0.165
Bivariate regression of cost variable on treatment arm, baseline costs, age and sex; outcome variable on treatment arm, baseline outcome,
age and sex, with correlation. Tested against no difference between groups.
Lower QALY scores denote reduced quality of life in the community arm compared to hospital.
*Higher HAQ scores denote worse clinical outcomes in the community arm compared to hospital.
†Higher costs—community arm is more expensive compared to hospital.
Figure 2 (A and B) Cost-effectiveness plane (complete data set); (C and D) Cost-effectiveness acceptability curve (complete
data set).
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matched at baseline in terms of disease severity. Baseline
imbalance with medication use was adjusted for in sensi-
tivity analysis. We found that care in the community was
associated with a non-signiﬁcant higher mean cost and
no clinically signiﬁcant change in effectiveness, as
assessed by EQ-5D and HAQ.
The number and subsequent cost of health profes-
sional visits and hospital admissions was very similar
between study arms. There was no evidence in our study
that access to physiotherapists, occupational therapists
and podiatrists was disrupted by care in the community.
Drug monitoring also was carried out to the same extent
with no evidence that visits to phlebotomists was
changed. The number of RP visits was greater in the
community. Surprisingly, given the model of care, the
number of rheumatologist visits was also slightly higher
in the community NLC group. This suggests that RPs
were referring back to rheumatologist more frequently.
In this model of care, rheumatologists were not provid-
ing care in the community. It is possible that isolation
from medical staff in the community resulted in an
increased referral for consultant opinions for matters
that might have been discussed informally during a
clinic visit between nurse and rheumatologist. Two
factors may have contributed to this: ﬁrst, the RPs did
not perform intra-articular injections; if they felt one was
required they referred back to the hospital clinic.
Second, they were not completely independent prescri-
bers and hence, if RA became uncontrolled and change
in drug therapy was required, referral was made back to
the consultant clinic. A survey of rheumatology nurses in
the UK in 2009 reported that 26% of rheumatology
nurses were able to independently prescribe and 33%
perform intra-articular joint injections.39
This study compliments previous studies which have
shown that NLC is an effective model when based in sec-
ondary care setting.13–15 40 41 However, it questions
whether community NLC, away from medical staff, is cost-
effective. The study by Ndosi provides good evidence that
hospital-based NLC is cost-effective and not inferior to
conventional RLC.14 In the present study there was no sig-
niﬁcant difference in clinical effectiveness, and no signiﬁ-
cant differences in costs There are however other reasons,
such as geographical proximity of the community services
to the patient’s home, to explain why particularly in rural
areas community based services may develop.
While the proportion of non-biological DMARDs and
opioid analgesics was relatively even and did not change
during the study period, we noted a large baseline
imbalance in participants using biological DMARDs,
which increased over the course of the study. Although
the sample sizes were small, baseline characteristics of
participants who were prescribed biological DMARDS
appeared similar to the rest of the study population.
The reasons for this imbalance are not clear. Even when
we adjust for baseline imbalance, this difference per-
sisted; as biological drugs are very expensive, this was a
major driver of the difference in costs. Use of biologics
in the UK is governed by strict criteria based on disease
activity. Patients recruited into the study were considered
to have stable disease irrespective of treatment. It is pos-
sible that there was a selection bias away from recruiting
patients taking biological agents in the hospital setting.
However, analysis excluding the patients receiving bio-
logical DMARDs at baseline showed that community
care may still be associated with greater costs.
Limitations of the study
The ﬁnal number of participants was less than planned;
both the groups remained matched in terms of age, sex
and size, but this limited our statistical power. Only 60%
and 61% of participants in the community and hospital
groups, respectively, completed all three sets of question-
naires. Data was only analysed for those patients for
whom we had a complete set of data for the variable(s)
in question, except for the sensitivity analysis in which
all cases were included after multiple imputation.
The study was not randomised and there may have
been disparities between the groups in characteristics
that were not measured and which might have impacted
on outcome. This was a pragmatic observational study
and normal pattern of care was continued. Decisions
about referral and appointment frequency were at the
discretion of the practitioner (nursing or medical)
seeing the patient. Joint counts were not performed rou-
tinely and therefore, we were unable to calculate disease
activity scores. However, other measures of outcome,
such as HAQ, were balanced at baseline and were
assessed at 6 and 12 months.
There are limits to the generalisability of the study: in
many regions, RPs are not sufﬁciently skilled to practice
independently in out-of-hospital settings. A key limita-
tion is prescribing ability. It is possible that some of the
differences in costs and in particular, rheumatologist
visits, was related to the limited prescribing authority of
the nurse practitioners. Thus, in the absence of nurse
prescribing, community clinics may be best run as joint
clinics with rheumatologists.
CONCLUSION
We conclude that community NLC may be associated
with non-signiﬁcant higher costs with no signiﬁcant dif-
ferences in clinical outcomes when compared with RLC
in secondary care and this suggests a low probability
that it is cost-effective. Cost-effectiveness might be
improved in the community if RPs were fully able to pre-
scribe independently and inject joints.
Acknowledgements The authors are very grateful to the patients and staff of
Attleborough, Fakenham, Holt, North Walsham, Sheringham, Thorpewood
(in Norwich) and Wymondham general practices, and the patients and staff of
the department of rheumatology Norfolk and Norwich University Hospital. The
study was adopted by UK Clinical Research Network (UKCRN ID 6629) and
was provided with infrastructure support. The authors thank the study team
Mr Andrew Walker and Ms Karly Graham, and Mrs Vivian Hawes patient and
public member of the trial steering committee.
Watts RA, et al. BMJ Open 2015;5:e007696. doi:10.1136/bmjopen-2015-007696 7
Open Access
Contributors RAW was the chief investigator and main grant holder, and
oversaw the project. DGIS and JM initially conceived the idea and contributed
to project design. AJM contributed to development of the project. GB and LS
developed the statistical approach to the study. GB and LI conducted the
health economic analysis. RAW, JM and GB had full access to the data in the
study and take full responsibility for the integrity of the data and accuracy of
data analysis. All authors reviewed and approved the final draft manuscript.
Funding This paper presents independent research funded by the National
Institute for Health Research (NIHR) under its Research for Patient Benefit
(RfPB) Programme (Grant Reference Number PB-PG-0407-13302). The views
expressed are those of the authors and not necessarily those of the NHS, the
NIHR or the Department of Health.
Competing interests None declared.
Patient consent Obtained.
Ethics approval Informed consent was obtained from all patients. Ethical
committee approval was obtained from the East Norfolk and Waveney
Research Ethics Committee. Research sponsorship was provided by
University of East Anglia.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid
arthritis in the United Kingdom: new estimates for a new century.
Rheumatology (Oxford) 2002;41:793–800.
2. Office NA. Services for people with rheumatoid arthritis. 2009.
3. Health D of. Improving Chronic Disease Management [Internet].
2004. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/
publicationsandstatistics/publications/publicationspolicyandguidance/
dh_4075214
4. Hill J. Rheumatology nurse specialists—do we need them?
Rheumatology (Oxford) 2007;46:379–81.
5. Van Eijk-Hustings Y, van Tubergen A, Boström C, et al. EULAR
recommendations for the role of the nurse in the management of
chronic inflammatory arthritis. Ann Rheum Dis 2012;71:13–19.
6. Leary A, Crouch H, Lezard A, et al. Dimensions of clinical nurse
specialist work in the UK. Nurs Stand 2008;23:40–4.
7. Oliver S, Leary A. The value of the nurse specialists’ role: Pandora
initial findings. Musculoskeletal Care 2010;8:175–7.
8. Hill J, Bird HA, Hopkins R, et al. The development and use of
Patient Knowledge Questionnaire in rheumatoid arthritis.
Br J Rheumatol 1991;30:45–9.
9. Hill J, Thorpe R, Bird H. Outcomes for patients with RA:
a rheumatology nurse practitioner clinic compared to standard
outpatient care. Musculoskeletal Care 2003;1:5–20.
10. Tijhuis GJ, Zwinderman AH, Hazes JMW, et al. Two-year follow-up
of a randomized controlled trial of a clinical nurse specialist
intervention, inpatient, and day patient team care in rheumatoid
arthritis. J Adv Nurs 2003;41:34–43.
11. Ndosi M, Vinall K, Hale C, et al. The effectiveness of nurse-led care
in people with rheumatoid arthritis: a systematic review. Int J Nurs
Stud 2011;48:642–54.
12. Abdelhamid A, Mooney J, Walker AA, et al. An evaluation of
rheumatology practitioner outreach clinics: a qualitative study.
BMC Health Serv Res 2012;12:119.
13. Van den Hout WB, Tijhuis GJ, Hazes JMW, et al. Cost effectiveness
and cost utility analysis of multidisciplinary care in patients with
rheumatoid arthritis: a randomised comparison of clinical nurse
specialist care, inpatient team care, and day patient team care.
Ann Rheum Dis 2003;62:308–15.
14. Ndosi M, Lewis M, Hale C, et al. The outcome and
cost-effectiveness of nurse-led care in people with rheumatoid
arthritis: a multicentre randomised controlled trial. Ann Rheum Dis
2014;73:1975–82.
15. Sørensen J, Primdahl J, Horn HC, et al. Shared care or nurse
consultations as an alternative to rheumatologist follow-up for
rheumatoid arthritis (RA) outpatients with stable low disease-activity
RA: cost-effectiveness based on a 2-year randomized trial. Scand J
Rheumatol 2015;44:13–21.
16. Bowling A, Bond M. A national evaluation of specialists’ clinics in
primary care settings. Br J Gen Pract 2001;51:264–9.
17. Bond M, Bowling A, Abery A, et al. Evaluation of outreach clinics
held by specialists in general practice in England. J Epidemiol
Community Health 2000;54:149–56.
18. Gruen RL, Weeramanthri TS, Knight SE, et al. Specialist outreach
clinics in primary care and rural hospital settings. Cochrane
Database Syst Rev 2004;(1):CD003798.
19. Arnett FC, Edworthy SM, Bloch DA, et al. The American
Rheumatism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
20. Cooper NJ, Mugford M, Symmons DPM, et al. Total costs and
predictors of costs in individuals with early inflammatory polyarthritis:
a community-based prospective study. Rheumatology (Oxford)
2002;41:767–74.
21. Curtis L. Unit costs of health and social care 2011. Personal Social
Services Research Unit, The University of Kent, 2011.
22. Department of Health. Reference Costs 2011–12. Department of
Health, 2012.
23. Office for National Statistics Annual Survey of Hours and Earnings,
2011 revised results (Soc 2010) [Internet]. http://www.ons.gov.uk/
ons/rel/ashe/annual-survey-of-hours-and-earnings/2011-revised-
results--soc-2010-/index.html
24. Drummond M, Sculpher M, Torrance G, et al. Methods for the
economic evaluaiton of health care programmes. 3rd edn.
New York: Oxford University Press, 2005.
25. Sach TH, Whynes DK. Measuring indirect costs: is there a problem?
Appl Health Econ Health Policy 2003;2:135–9.
26. NHS. NHS: the information centre for health and social care
prescription cost analysis, England—2012. Health and social care
information centre, Health and social care information centre,
Prescribing and primary care servies, 2013.
27. Brooks R. EuroQol: the current state of play. Health Policy
1996;37:53–72.
28. Dolan P. Modeling valuations for EuroQol health states. Med Care
1997;35:1095–108.
29. Sach TH, Barton GR, Jenkinson C, et al. Comparing cost-utility
estimates: does the choice of EQ-5D or SF-6D matter? Med Care
2009;47:889–94.
30. NICE. Guide to the methods of technology appraisal 2013. NICE
Publications, 2013.
31. Little RJ, Rubin DB. Statistical analysis with missing data. 2nd edn.
Hoboken: Wiley, 2002:1–408.
32. Royston P. Multiple imputation of missing values. Stata J
2004;4:227–41.
33. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in
trial-based cost-effectiveness analysis: the importance of controlling
for baseline utility. Health Econ 2005;14:487–96.
34. Briggs A, Clark T, Wolstenholme J, et al. Missing…presumed at
random: cost-analysis of incomplete data. Health Econ
2003;12:377–92.
35. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness
analysis up by its bootstraps: a non-parametric approach to
confidence interval estimation. Health Econ 1997;6:327–40.
36. Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability
curves—facts, fallacies and frequently asked questions. Health Econ
2004;13:405–15.
37. Heyse J, Cook J, Carides G. Statistical considerations in analysing
health care resource utilization and cost data. In: Drummond M,
McGuire A, eds. Economic evaluation in health care. Oxford: Oxford
University Press, 2001:215–35.
38. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire:
dimensions and practical applications. Health Qual Life Outcomes
2003;1:20.
39. Royal College of Nursing. Rheumatology Nursing. 2009.
https://www.rcn.org.uk/__data/assets/pdf_file/0004/…/003524.pdf
40. Primdahl J, Sørensen J, Horn HC, et al. Shared care or nursing
consultations as an alternative to rheumatologist follow-up for
rheumatoid arthritis outpatients with low disease activity—patient
outcomes from a 2-year, randomised controlled trial. Ann Rheum Dis
2014;73:357–64.
41. Koksvik HS, Hagen KB, Rødevand E, et al. Patient satisfaction with
nursing consultations in a rheumatology outpatient clinic: a 21-month
randomised controlled trial in patients with inflammatory arthritides.
Ann Rheum Dis 2013;72:836–43.
8 Watts RA, et al. BMJ Open 2015;5:e007696. doi:10.1136/bmjopen-2015-007696
Open Access
